^
    1d
    NCI-2021-09185: Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=24, Recruiting, City of Hope Medical Center | Trial completion date: Feb 2026 --> May 2026 | Trial primary completion date: Feb 2026 --> May 2026
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • cyclophosphamide • methotrexate • vincristine • daunorubicin • Oncaspar liquid (pegaspargase) • mercaptopurine • Starasid (cytarabine ocfosfate)
    1d
    SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=53, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jan 2027
    Trial completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CD4 (CD4 Molecule) • CSF1R (Colony stimulating factor 1 receptor)
    |
    ABL2 fusion
    |
    dasatinib • Blincyto (blinatumomab) • methotrexate • vincristine • mercaptopurine • Xatmep (methotrexate oral solution)
    2d
    Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=97, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD22 (CD22 Molecule) • CD5 (CD5 Molecule) • CD79A (CD79a Molecule) • MME (Membrane Metalloendopeptidase) • CD7 (CD7 Molecule) • ANPEP (Alanyl Aminopeptidase, Membrane) • MPO (Myeloperoxidase)
    |
    dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • sirolimus • leucovorin calcium • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
    3d
    Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, Novartis Pharmaceuticals | N=140 --> 61
    Enrollment change
    |
    CD19 positive
    |
    PIT565
    4d
    Self-reinforcing IL-1b signaling accelerates the development and recurrence of TCF3::HLF-positive B-ALL. (PubMed, Blood)
    Importantly, single-cell RNA-seq of patient samples demonstrated strong IL1B induction at relapse compared with diagnosis, underscoring its clinical relevance. Collectively, these findings establish the TCF3::HLF-IL-1β axis as a critical determinant of leukemic propagation and bone pathology, and highlight IL-1β blockade as a potential therapeutic strategy for this otherwise incurable leukemia.
    Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TCF3 (Transcription Factor 3) • IL1B (Interleukin 1, beta) • IL1R1 (Interleukin 1 receptor, type I) • TNFSF11 (TNF Superfamily Member 11)
    4d
    Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov)
    P1, N=16, Recruiting, Chulalongkorn University | Not yet recruiting --> Recruiting | Initiation date: Sep 2025 --> Jan 2026
    Enrollment open • Trial initiation date
    |
    IL7R (Interleukin 7 Receptor)
    |
    CD19 positive
    5d
    A041501: Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P3, N=310, Suspended, Alliance for Clinical Trials in Oncology | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule) • ITGB1 (Integrin Subunit Beta 1)
    |
    CD20 positive • CD22 positive
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Besponsa (inotuzumab ozogamicin) • vincristine • daunorubicin • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine
    8d
    GREM1 promotes leukemic survival via PI3K/AKT signaling in infant MLL-AF4-positive B-ALL. (PubMed, Exp Hematol)
    Together, these findings identify GREM1 as a leukemia cell-associated regulator of survival in infant MLL-AF4-positive B-ALL and implicate PI3K/AKT signaling as a key downstream mediator, suggesting that GREM1-associated survival pathways may represent a potential vulnerability in this aggressive leukemia subtype. TEASER ABSTRACT: GREM1 is overexpressed in infant MLL-AF4-positive B-ALL and promotes leukemic cell survival by activating PI3K/AKT signaling, making it a potential therapeutic target.
    Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • KMT2A (Lysine Methyltransferase 2A) • AFF1 (AF4/FMR2 Family Member 1) • GREM1 (Gremlin 1)
    9d
    Adult Patients with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Multiagent Chemotherapy Regimen, in Combination with a TKI, Do Not Require Routine alloSCT. (PubMed, Curr Oncol)
    At Princess Margaret Hospital (PM), adult patients with Ph+ B-ALL have been treated with a pediatric-inspired chemotherapy protocol with mostly imatinib...Patient outcomes improved iteratively, with the best results seen in the final (2016-2019) cohort: no asparaginase, no routine alloSCT referral in CR1; 4-year overall survival (OS) and relapse-free survival (RFS) were 87.0% and 69.3%, respectively. The long-term OS in this patient group retained statistical significance in the multivariable analysis (p = 0.0176) when BCR::ABL1 molecular measurable residual disease (MRD) was considered.
    Journal
    |
    ABL1 (ABL proto-oncogene 1)
    |
    imatinib
    9d
    Intra-subtype heterogeneity shapes treatment response in KMT2A-rearranged ALL across all age groups. (PubMed, Hemasphere)
    Notably, good responders to ex vivo induction drugs were characterized by a higher maturity score (P = 1.8E-03), whereas for less mature KMT2Ar B-ALL cases, response profiles suggested higher Venetoclax sensitivity. Our study provides an integrative framework linking developmental phenotype, fusion partner, and MRD kinetics across the full age spectrum of KMT2Ar B-ALL. These insights may support future risk-adapted strategies and therapeutic targeting, particularly in immature KMT2Ar B-ALL.
    Journal
    |
    KMT2A (Lysine Methyltransferase 2A) • AFF1 (AF4/FMR2 Family Member 1)
    |
    Venclexta (venetoclax)
    9d
    An Engineered Adeno-Associated Virus Variant Enables Efficient Gene Editing in Human T Cells. (PubMed, Hum Gene Ther)
    Simultaneously, programmed cell death protein 1 (PD-1) knockout and CAR overexpression were achieved in human primary T cells using Tot3, with knockout and knock-in efficiencies reaching up to 70% and 55%, respectively. These CAR-T cells demonstrated significantly enhanced antitumor activity and increased survival times in a mouse model of diffuse B cell lymphoma.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1)
    10d
    ECOG-ACRIN EA9152: Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=40, Active, not recruiting, ECOG-ACRIN Cancer Research Group | N=74 --> 40 | Trial primary completion date: Dec 2025 --> Jul 2025
    Enrollment change • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • vincristine • Marqibo (vincristine liposomal)